

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/076669 A1

(51) International Patent Classification:

A61K 39/155 (2006.01) C07K 14/135 (2006.01)

A61K 39/39 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2021/053944

(22) International Filing Date:

07 October 2021 (07.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/089,978 09 October 2020 (09.10.2020) US

(71) Applicant: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th Street, Austin, TX 78701 (US).

(72) Inventors: **MCLELLAN, Jason**; c/o University of Texas, Molecular Biosciences, 100 E. 24th Street, Austin, TX 78712 (US). **HSIEH, Ching-Lin**; c/o University of Texas, Molecular Biosciences, 100 E. 24th Street, Austin, TX 78712 (US). **RUSH, Scott**; c/o University of Texas, Molecular Biosciences, 100 E. 24th Street, Austin, TX 78712 (US). **WANG, Nianshuang**; c/o University of Texas, Molecular Biosciences, 100 E. 24th Street, Austin, TX 78712 (US).

(74) Agent: **SCHNEPP, Amanda, S., J.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PREFUSION-STABILIZED HMPV F PROTEINS

(57) Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

WO 2022/076669 A1